DrugPatentWatch Database Preview
Teva Pharm Company Profile
What is the competitive landscape for TEVA PHARM, and when can generic versions of TEVA PHARM drugs launch?
TEVA PHARM has two hundred and seventy-nine approved drugs.
There are thirty-three US patents protecting TEVA PHARM drugs. There are thirty-four tentative approvals on TEVA PHARM drugs.
Summary for Teva Pharm
| US Patents: | 33 |
| Tradenames: | 233 |
| Ingredients: | 226 |
| NDAs: | 279 |
| Patent Litigation for Teva Pharm: | See patent lawsuits for Teva Pharm |
| PTAB Cases with Teva Pharm as petitioner: | See PTAB cases with Teva Pharm as petitioner |
Drugs and US Patents for Teva Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Usa | IFOSFAMIDE/MESNA KIT | ifosfamide; mesna | INJECTABLE;INTRAVENOUS | 075874-001 | Feb 26, 2002 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
| Teva Pharm | AIRDUO RESPICLICK | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 208799-001 | Jan 27, 2017 | RX | Yes | No | 9,987,229 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Teva Pharms Usa | OCTREOTIDE ACETATE | octreotide acetate | INJECTABLE;INJECTION | 075957-003 | Oct 3, 2005 | AP | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Teva Pharms | AZITHROMYCIN | azithromycin | FOR SUSPENSION;ORAL | 065419-001 | Jun 24, 2008 | AB | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Teva Pharms Usa | CARBOPLATIN | carboplatin | INJECTABLE;IV (INFUSION) | 077139-004 | Sep 21, 2005 | AP | RX | No | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Teva Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-003 | Jan 28, 2014 | 6,054,430 | ➤ Try a Free Trial |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-002 | Feb 12, 2002 | 8,367,605 | ➤ Try a Free Trial |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-002 | Feb 12, 2002 | 7,199,098 | ➤ Try a Free Trial |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-002 | Feb 12, 2002 | 6,939,539 | ➤ Try a Free Trial |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | FOR SOLUTION;SUBCUTANEOUS | 020622-001 | Dec 20, 1996 | 6,939,539 | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA PHARM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsule | 15 mg and 30 mg | ➤ Subscribe | 2008-08-11 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-02-26 |
| ➤ Subscribe | for Injection | 3.5 mg/vial | ➤ Subscribe | 2016-10-26 |
| ➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-01-29 |
Premature patent expirations for TEVA PHARM
Expiration due to failure to pay maintenance fee
| Patent Number | Expiration Date |
|---|---|
| ➤ Try a Free Trial | ➤ Try a Free Trial |
International Patents for Teva Pharm Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| South Korea | 101471739 | ➤ Try a Free Trial |
| Spain | 2343511 | ➤ Try a Free Trial |
| Spain | 2544277 | ➤ Try a Free Trial |
| China | 104784791 | ➤ Try a Free Trial |
| South Africa | 201307990 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Teva Pharm Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C/GB06/008 | United Kingdom | ➤ Try a Free Trial | PRODUCT NAME: ERLOTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OR POLYMORPH THEREOF, IN PARTICULAR THE HYDROCHLORIDE SALT; REGISTERED: CH 5726601 20050321; CH 5726602 20050321; CH 5726603 20050321; UK EU/1/05/311/001 20050919; UK EU/1/05/311/002 20050919; UK EU/1/05/311/003 20050919 |
| C/GB97/010 | United Kingdom | ➤ Try a Free Trial | PRODUCT NAME: GENERIC NAME: IRINOTECANCHEMICAL NAME: (+)-(4S)-4,11-DIETHYL-4-HYDROXY-9-((4-PIPERIDINOPIPERIDINO)CARBONYLOXY)-1H-PYRANO (3',4':6,7) INDOLIZINO(1,2-B) QUINOLINE-3,14-(4H,12H)-DIONE,OPTIONALLY THE HYDROCHLORIDE SALT THEREOF AND OPTIONALLY THE TRIHYDRATE T; REGISTERED: FR 558822.2 19950505; FR 558823.9 19950505; FR 558824.5 19950505; FR 558825.1 19950505; UK 00012/0302 19961017; UK 00012/0303 19961017 |
| 00125 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106 |
| C0004 | Belgium | ➤ Try a Free Trial | PRODUCT NAME: ESTRADIOL, HEMIHYDRATE, NORETHISTERONE, ACETATE; NAT. REGISTRATION NO/DATE: NL 23753 19981210; FIRST REGISTRATION: SE - 14 007 19980306 |
| 2017000006 | Germany | ➤ Try a Free Trial | PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
